Synthesis, anti-inflammatory and analgesic activity of 2-[4-(substituted benzylideneamino)-5-(substituted phenoxymethyl)-4H-1,2,4-triazol-3-yl thio] acetic acid derivatives  by Hunashal, R.D. et al.
Arabian Journal of Chemistry (2014) 7, 1070–1078King Saud University
Arabian Journal of Chemistry
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLESynthesis, anti-inﬂammatory and analgesic activity
of 2-[4-(substituted benzylideneamino)-5-
(substituted phenoxymethyl)-4H-1,2,4-triazol-3-yl
thio] acetic acid derivatives* Corresponding author. Tel.: +91 836 2278097; fax: +91 0836
2373724.
E-mail address: rajeshrd3@rediffmail.com (R.D. Hunashal).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.arabjc.2011.01.003
1878-5352 ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.R.D. Hunashal a,*, P.M. Ronad b, V.S. Maddi b, D. Satyanarayana c,
M.A. Kamadod aa Department of Pharmacology, Karnataka Institute of Medical Sciences, Hubli 580 021, Karnataka, India
b Department of Pharmaceutical Chemistry, K.L.E.S’s College of Pharmacy, Hubli 580 031, Karnataka, India
c Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences, Paneer, Deralakatte,
Mangalore 574 160, Karnataka, IndiaReceived 26 November 2010; accepted 4 January 2011
Available online 8 January 2011KEYWORDS
1,2,4-Triazole;
Schiff Base;
1,2,4-Triazolyl thioacetic
acid;
Anti-inﬂammatory activity;
Analgesic activityAbstract The title compounds 3a–l have been synthesized by the reaction of thiocarbohydrazide
with substituted phenoxy acetic acid to obtained substituted 1,2,4-triazoles (1). Compound 1 was
treated with various substituted aromatic aldehydes which results in 4-(substituted benzylideneami-
no)-5-(substituted phenoxymethyl)-2H-1,2,4-triazol-3(4H)-thiones (2a–g), further 2a–g is converted
to 2-[4-(substituted benzylideneamino)-5-(substituted phenoxymethyl)-4H-1,2,4-triazol-3-yl thio]
acetic acid (3a–l) derivatives by the reaction with chloroacetic acid. All the newly synthesized
compounds were evaluated for in vivo anti-inﬂammatory and analgesic activities. Among the series
2-[4-(2,4-dichlorobenzylideneamino)-5-(phenoxymethyl)-4H-1,2,4-triazol-3-yl thio] acetic acid (3d),
2-[4-(4-dichlorobenzylideneamino)-5-(phenoxymethyl)-4H-1,2,4-triazol-3-yl thio] acetic acid (3e),
2-[4-(2,4-dichlorobenzylideneamino)-5-[(2,4-dichlorophenoxy)methyl]-4H-1,2,4-triazol-3-yl thio]
Synthesis, anti-inﬂammatory and analgesic activity 1071acetic acid (3j) and 2-[5-[(2,4-dichlorophenoxy)methyl)]-4-(4-chlorobenzylideneamino)-4H-1,2,4-
triazol-3-yl thio] acetic acid (3k) showed signiﬁcant anti-inﬂammatory activity with P< 0.001
(63.4%, 62.0%, 64.1% and 62.5% edema inhibition, respectively), as compared to the standard
drug diclofenac (67.0%) after third hour respectively and also compounds 3j, 3k exhibited signiﬁ-
cant analgesic activity with P< 0.001 (55.9% and 54.9% protection, respectively) and less ulcero-
genic activity as compared with standard drug aspirin (57.8%).
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Inﬂammation is a defensive but exaggerated local tissue
reaction in response to exogenous or endogenous insult. Cyclo-
oxygenase (COX) and 5-lipoxygenase (5-LO) are enzymes
which catalyze the rate-limiting steps in the biosynthesis of
prostaglandins and leukotrienes from arachidonic acid. A
large number of non-steroidal anti-inﬂammatory drugs (NSA-
IDs) are available clinically to treat inﬂammatory disorders.
The most important mechanism of anti-inﬂammatory action
of NSAIDs is considered to be primarily by inhibition of pros-
taglandin synthesis. The principal side effects associated with
chronic use of non selective NSAIDs are gastrointestinal irrita-
tion, bleeding and formation of life threatening gastrointesti-
nal ulcer. In addition, there is evidence to suggest that
leukotriene promotes gastric ulceration, which limits the ther-
apeutic utilization of these drugs (Lombardino, 1985; Mullican
et al., 1993; Osiri and Moreland, 1999). Therefore, there is a
need to develop new compounds. Literature survey revealed
that Schiff bases of 1,2,4-triazoles bearing aryl groups or het-
erocyclic residues (Olcay et al., 2006) which possess excellent
biological activities, viz. antibacterial (Francis et al., 2008),
antifungal (Desai et al., 1984), antitubercular (Iraj et al.,
2008; Kucukguzel et al., 2008), anticancer (Mahendra et al.,
2007; Upadhaya et al., 2004), anti-inﬂammatory (Fahmy and
Soliman, 2001; Latifeh et al., 2006; Yasemin et al., 2007) and
anticonvulsant activities (Almarirad, 2004).
In view of these facts and in continuation of our research
program on synthesis and pharmacological importance of var-
ious heterocyclic Schiff bases (Ronad et al., 2008a, 2008b;
Maddi et al., 1992; Hunashal et al., 2010), now we are report-
ing the synthesis, anti-inﬂammatory and analgesic activity of
2-[4-(substituted benzylideneamino)-5-(substituted phenoxy-
methyl)-4H-1,2,4-triazol-3-yl thio] acetic acid derivatives.
Compounds which showed signiﬁcant activity in acute anti-
inﬂammatory model were further screened for analgesic and
ulcerogenic activity.2. Experimental
2.1. General considerations
All research chemicals were purchased from Acros organics
(NY, USA), Sigma–Aldrich (St. Loius, Missouri, USA), Lan-
caster Co. (Ward Hill, MA, USA) and used as such for the
reactions. Solvents except laboratory reagent grade were dried
and puriﬁed according to the literature whenever necessary.
Puriﬁcation of title compounds were carried out by ﬂash
chromatography from Biotage Isolera ST-1 (Darmstadt,
Germany). Reactions were monitored by thin layer chroma-tography (TLC) on pre-coated silica gel plates from E. Merck
and Co. (Darmstadt, Germany).
Melting points of synthesized compounds were determined
in Thermonik melting point apparatus (Chennai, India) and
are uncorrected. The IR spectra were recorded on Thermo
Nicolet FTIR-200 Spectrometer (Madison, WI, USA), using
KBr pellets. The 1H NMR and 13C NMR were recorded on
Bruker AVANCE II 400 (Bruker, Rheinstetten/Karlsruhe,
Germany) in CDCl3/DMSO-d6 as solvent. Chemical shifts are
reported in d ppm units with respect to TMS. The mass spectra
were recorded using GCMS-QP 2010 (Shimaduzu, Japan). The
anti-inﬂammatory activity was carried out using digital plethys-
mometer (Ugo-Basile, Italy). All the animal experiments were
approved by Institutional Animal Ethical Committee (IAEC).
2.2. Synthesis
2.2.1. General method for synthesis of 3-(substituted
phenoxymethyl)-4-amino-5-mercapto 1,2,4-triazole (1)
An intimate mixture of thiocarbohydrazide (1.06 g, 0.01 mol)
and substituted phenoxy acetic acid (0.01 mol) was heated in
an oil bath at 175–180 C for 2 h. The fused mass was tritu-
rated with hot water, ﬁltered and washed with sodium bicar-
bonate. The crude product was recrystallized from methanol.
2.2.1.1. 3-(Phenoxymethyl)-4-amino-5-mercapto 1,2,4-triazole
(1a). C9H10N4OS, mp 186–187 C, Yield is 69.0%.
IR (KBr, cm1): 3215.4 (NH2), 3209.4 (NH), 2363.2 (SH),
1628.3, 1589.2 (C‚N).
1H NMR (DMSO-d6, d ppm): 13.6 (br, 1H, SH), 7.6–6.9
(m, 5H, Ar-H), 5.1 (s, 2H, OCH2) and 3.3 (s, 2H, NH2).
MS (ESI) (M+): m/z 222.0; calcd. 222.2.
2.2.1.2. 3-(2,4-Dichloro phenoxymethyl)-4-amino-5-mercapto
1,2,4-triazole (1b). The compound was further puriﬁed by
ﬂash chromatography using dimethyl formamide (DMF) and
methanol as mobile phase.
C9H8Cl2N4OS, mp 130–132 C, Yield is 62.6%.
IR (KBr, cm1): 3457.4 (NH2), 3241.1 (NH), 1620.6
(C‚N), 1282.1 (C‚S), 781.5 (C–Cl).
1H NMR (400 MHz, DMSO-d6 dppm): 7.8–6.8 (m, 3H,
Ar-H and NH), 4.5 (s, 2H, OCH2), 2.1 (s, 2H, NH2).
2.2.2. General method for synthesis of 4-(substituted
benzylideneamino)-5-(substituted phenoxymethyl)-2H-1,2,4-
triazole-3(4H)-thione (2a–g)
A mixture of N0-4-amino-5-(substituted phenoxymethyl)-2H-
1,2,4-triazole-3(4H)-thione (1) (0.01 mol) and the correspond-
ing various aromatic aldehydes (0.01 mol) in ethanol (25 ml)
was treated with concentrated HCl (0.5 ml) and reﬂuxed for
2 h. The reaction mixture was cooled to room temperature
1072 R.D. Hunashal et al.and the separated crystalline compound is ﬁltered and recrys-
tallized from ethanol to give 2a–g.
2.2.2.1. 4-(4-Methylbenzylideneamino)-5-(phenoxymethyl)-
4H-1,2,4-triazolo-3-thiol (2a). IR (KBr, cm1): 3054.3
(Ar-H), 2916.8 (OCH2), 2755.2 (SH), 1594.0 (HC‚N),
1534.5 (C‚N).
1H NMR (400 MHz, CDCl3, d ppm): 10.5 (br, 1H, SH),
10.2 (s, 1H, HC‚N), 7.2–6.9 (m, 9H, Ar-H), 5.2 (s, 2H,
OCH2), 2.4 (s, 3H, CH3).
MS (ESI) (M+1): 325.3; calcd. 324.4.
13C NMR (400 MHz, CDCl3, d ppm): 163.4 (triazole-C3),
146.7 (triazole-C5), Ar C [158.9 (C1), 129.3 (C3 and C5),
123.3 (C6), 122.2 (C4), 115.3 (C2)], 155.9 (–CH‚N), Ar C
(benzylidene) [139.8 (C4), 131.2 (C3 and C5), 130.2 (C2 and
C6), 129.9 (C1)], 68.9 (OCH2), 61.2 (OCH3), 24.5 (CH3).
2.2.2.2. 4-(4-Nitrobenzylideneamino)-5-[(2,4-dichlorophen-
oxy)methyl]-2H-1,2,4-triazolo-3(4H)-thione (2b). IR (KBr,
cm1): 3050.4 (Ar C–H), 2461.2 (SH), 1592.3 (HC‚N),
1545.7 (NO2), 1531.3 (C‚N), 1285.7 (C‚S), 825.3 (C–Cl).
1H NMR (400 MHz, DMSO-d6, d ppm): 12.8 (s, 1H, SH),
8.9 (s, 1H, HC‚N), 7.4–6.8 (m, 7H, Ar-H), 5.2 (s, 2H, OCH2).
13C NMR (400 MHz, DMSO-d6, d ppm): 152.8 (triazole-
C3), 176.9 (triazole-C5), Ar C [152.1 (C1), 130.3 (C5), 128.3
(C3 and C4), 124.2 (C6), 116.3 (C2)], 142.3 (HC‚N), Ar C
(benzylidene) [139.6 (C1), 138.6 (C2 and C4), 127.6 (C6),
120.6 (C3 and C5)], 64.8 (OCH2).
MS (ESI): m/z 424.2; calcd. 424.0.
2.2.2.3. 4-(4-Methoxyoxybenzylideneamino)-5-[(2,4-dichloro-
phenoxy)methyl]-2H-1,2,4-triazolo-3(4H)-thione (2c). IR
(KBr, cm1): 3061.1 (Ar C–H), 2924.3 (OCH2), 2547.2 (SH),
1606.5 (HC‚N), 1537.3 (C‚N), 824.5 (C–Cl).
1H NMR (400 MHz, DMSO-d6, d ppm): 11.6 (s, 1H, SH),
8.1 (s, 1H, N‚CH), 7.7–6.9 (m, 7H, Ar-H), 5.2 (s, 2H, OCH2),
3.3 (s, 3H, OCH3).
13C NMR (400 MHz, DMSO-d6, d ppm): 154.8 (triazole-
C3), 182.8 (triazole-C5), Ar C [153.1 (C1), 131.8 (C5), 128.7
(C3 and C4), 123.3 (C6), 116.9 (C2)], 142.9 (HC‚N), Ar C
(benzylidene) [161.7 (C4), 130.5 (C2 and C6), 125.3 (C1),
114.7 (C3 and C5)], 68.9 (OCH2), 60.2 (OCH3).
2.2.2.4. 4-(2-Hydroxybenzylideneamino)-5-[(2,4-dichlorophen-
oxy)methyl]-2H-1,2,4-triazolo-3(4H)-thione (2d). IR (KBr,
cm1): 3093.8 (OH), 3063.3 (Ar C–H), 2926.3 (OCH2),
2547.8 (SH), 1596.3 (HC‚N), 1532.5 (C‚N), 826.2 (C–Cl).
1H NMR (400 MHz, DMSO-d6, d ppm): 11.6 (br, 1H, SH),
10.2 (s, 1H, HC‚N), 8.3 (s,1H, OH), 7.3–6.9 (m, 7H, Ar-H),
5.2 (s, 2H, OCH2).
MS (ESI) (M+1): 396.2; calcd. 395.2.
2.2.2.5. 4-(2,4-Dichlorobenzylideneamino)-5-[(2,4-dichloro-
phenoxy)methyl]-2H-1,2,4-triazolo-3(4H)-thione (2e). IR
(KBr, cm1): 3055.5 (Ar C–H), 2925.4 (OCH2), 2554.2 (SH),
1610.4 (HC‚N), 1532.7 (C‚N), 834.2 (C–Cl).
1H NMR (400 MHz, DMSO-d6, d ppm): 11.3 (s, 1H, SH),
8.4 (s, 1H, HC‚N), 7.3–6.9 (m, 6H, Ar-H), 5.2 (s, 2H, OCH2).
13C NMR (400 MHz, DMSO-d6, d ppm): 154.4 (triazole-
C3), 180.7 (triazole-C5), Ar C [152.4 (C1), 131.3 (C5), 128.2
(C3 and C4), 124.7 (C6), 116.8 (C2)], 142.7 (HC‚N), Ar C(benzylidene) [129.6 (C1), 136.4 (C2 and C4), 133.0 (C6),
128.6 (C3 and C5)], 68.9 (OCH2).
MS (ESI): m/z 448.1; calcd. 448.0.
2.2.2.6. 4-(4-Chlorobenzylideneamino)-5-[(2,4-dichlorophen-
oxy)methyl]-2H-1,2,4-triazolo-3(4H)-thione (2f). IR (KBr,
cm1): 3039.2 (Ar C–H), 2916.4 (OCH2), 2543.6 (SH), 1608.7
(HC‚N), 1533.8 (C‚N), 826.7 (C–Cl).
1H NMR (400 MHz, DMSO-d6, d ppm): 10.9 (s, 1H, SH),
8.2 (s, 1H, HC‚N), 7.3–6.9 (m, 7H, Ar-H), 5.2 (s, 2H, OCH2).
MS (ESI) (M+1): m/z 413.7; calcd. 412.0.
2.2.2.7. 4-(4-Methylbenzylideneamino)-5-[(2,4-dichlorophen-
oxy)methyl]-2H-1,2,4-triazolo-3(4H)-thione (2g). IR (KBr,
cm1): 3039.8 (Ar-H), 2927.4 (OCH2), 2564.6 (SH), 1604.5
(C‚N), 825.3 (C–Cl).
1H NMR (400 MHz, DMSO-d6, d ppm): 11.3 (br, 1H, SH),
9.2 (s, 1H, HC‚N), 7.3–6.8 (m, 7H, Ar-H), 5.2 (s, 2H, OCH2),
2.5 (s, 3H, CH3).
2.2.3. General method for synthesis of 2-[4-(substituted
benzylideneamino)-5-(substituted phenoxymethyl)-4H-1,2,4-
triazol-3-yl thio] acetic acid (3a–l)
Equimolar proportions of 2a–g and chloroacetic acid were dis-
solved in ethanol containing 3–4 drops of pyridine and re-
ﬂuxed for 2–3 h, on pouring the reaction mixture into cold
water a solid 3a–l was separated which was ﬁltered, washed
with water and recrystallized from ethanol to give 3a–l.
2.2.3.1. 2-[4-(4-Nitrobenzylideneamino)-5-(phenoxymethyl)-
4H-1,2,4-triazol-3-yl thio] acetic acid (3a). IR (KBr, cm1):
3200.0 (OH), 3068.9 (Ar C–H), 2928.4 (OCH2), 2374.2
(CH2), 1715.6 (C‚O), 1590.1 (C‚N), 1580.4 (NO2).
1H NMR (400 MHz, DMSO-d6, d ppm): 13.8 (s, 1H, OH),
10.8 (s, 1H, HC‚N), 8.2–6.9 (m, 9H, Ar-H), 5.1 (s, 2H,
OCH2), 1.1 (s, 2H, CH2).
13C NMR (400 MHz, CDCl3, d ppm): 178.0 (C‚O), 162.8
(triazole-C3), 157.9 (triazole-C5), Ar C [156.1 (C1), 129.3 (C3
and C5), 124.0 (C4 and C6), 115.1 (C2)], 162.8 (HC‚N), Ar
C (benzylidene) [149.6 (C1), 138.6 (C4), 129.6 (C3 and C5),
127.6 (C2 and C6)], 59.8 (OCH2), 29.5 (S–CH2).
MS (ESI): m/z 413.3; calcd. 413.4.
2.2.3.2. 2-[4-(4-Methoxybenzylideneamino)-5-(phenoxy-
methyl)-4H-1,2,4-triazol-3-yl thio] acetic acid (3b). IR (KBr,
cm1): 3117.6 (OH), 3056.3 (Ar C–H), 2952.6 (OCH2),
2755.3 (CH2), 1733.4 (C‚O), 1598.5 (C‚N).
1H NMR (400 MHz, CDCl3, d ppm): 13.7 (s, 1H, OH), 10.0
(s, 1H, N‚CH), 7.7–6.8 (m, 9H, Ar-H), 5.2 (s, 2H, OCH2), 3.7
(s, 3H, OCH3), 1.1 (s, 2H, CH2).
13C NMR (400 MHz, DMSO-d6, d ppm): 169.3 (C‚O),
162.0 (triazole-C3), 146.6 (triazole-C5), Ar C [157.3 (C1),
129.1 (C3 and C5), 114.6 (C4), 113.9 (C2 and C6)], 162.6
(–CH‚N), Ar C (benzylidene) [130.6 (C4), 130.1 (C1), 124.4
(C2 and C6), 121.3 (C3 and C5)], 59.3 (OCH2), 55.0 (OCH3),
38.9 (S–CH2).
2.2.3.3. 2-[4-(4-Methylybenzylideneamino)-5-(phenoxymethyl)-
4H-1,2,4-triazol-3-yl thio] acetic acid (3c). IR (KBr, cm1):
3200.2 (OH), 3055.2 (Ar-H), 2916.5 (OCH2), 2755.2 (CH2),
1734.0 (C‚O), 1594.7 (C‚N).
Synthesis, anti-inﬂammatory and analgesic activity 10731H NMR (400 MHz, CDCl3, d ppm): 13.5 (br, 2H, 2-OH),
10.2 (br, 1H, HC‚N), 7.5–6.8 (m, 9H, Ar-H), 5.1 (s, 2H,
OCH2), 1.2 (s, 2H, CH2).
13C NMR (400 MHz, DMSO-d6, d ppm): 169.3 (C‚O),
157.3 (triazole-C3), 136.9 (triazole-C5), Ar C [134.4 (C1),
129.6 (C3 and C5), 115.9 (C2 and C6), 117.3 (C4)], 157.3
(HC‚N), Ar C (benzylidene) [159.4 (C2), 132.1 (C5), 122.0
(C1 and C3), 119.9 (C4 and C6)], 59.9 (OCH2), 39.4 (S–CH2).
MS (ESI) (M2): m/z 382.4; calcd. 384.4.
2.2.3.4. 2-[4-(2,4-Dichlorobenzylideneamino)-5-(phenoxy-
methyl)-4H-1,2,4-triazol-3-yl thio] acetic acid (3d). IR (KBr,
cm1): 3200.0 (OH), 3051.3 (Ar C–H), 2920.4 (OCH2),
2373.5 (CH2), 1735.1 (C‚O), 1589.5 (C‚N).
1H NMR (400 MHz, DMSO-d6, d ppm): 13.9 (s, 1H, OH),
11.0 (s, 1H, HC‚N), 7.9–6.9 (m, 9H, Ar-H), 5.2 (s, 2H,
OCH2), 1.2 (s, 2H, CH2).
2.2.3.5. 2-[4-(4-Chlorobenzylideneamino)-5-(phenoxymethyl)-
4H-1,2,4-triazol-3-yl thio] acetic acid (3e). IR (KBr, cm1):
3200.2 (OH), 3050.5 (Ar C–H), 2914.8 (OCH2), 2373.8
(CH2), 1716.4 (C‚O), 1591.0 (C‚N).
1H NMR (400 MHz, CDCl3, d ppm): 13.8 (s, 1H, OH), 10.5
(s, 1H, HC‚N), 7.7–6.9 (m, 9H, Ar-H), 5.2 (s, 2H, OCH2), 2.5
(br, 2H, CH2).
2.2.3.6. 2-[4-(2-Hydroxybenzylideneamino)-5-(phenoxymethyl)-
4H-1,2,4-triazol-3-yl thio] acetic acid (3f). IR (KBr, cm1):
3098.8 (OH), 3051.2 (Ar C–H), 2915.9 (OCH2), 2751.6
(CH2), 1734.9 (C‚O), 1595.4 (C‚N).
1H NMR (400 MHz, DMSO-d6, d ppm): 13.7 (s, 1H, OH),
10.1 (s, 1H, HC‚N), 7.6–6.8 (m, 9H, Ar-H), 5.1 (s, 2H,
OCH2), 2.3 (s, 3H, CH3), 1.1 (s, 2H, CH2).
13C NMR (400 MHz, DMSO-d6, d ppm): 162.5 (C‚O),
162.5 (triazole-C3), 143.1 (triazole-C5), Ar C [157.9 (C1),
129.6 (C3 and C5), 121.8 (C4), 115.1 (C2 and C6)], 147.2
(–CH‚N), Ar C (benzylidene) [129.7 (C4), 129.5 (C2 and
C6), 129.1 (C1), 128.7 (C3 and C5)], 59.8 (OCH2), 39.4 (S–
CH2), 21.7 (CH3).
MS (ESI) (M1): m/z 381.4; calcd. 382.4.
2.2.3.7. 2-{5-[(2,4-Dichlorophenoxy)methyl]-4-(4-nitrobenzy-
lideneamino)-4H-1,2,4-triazol-3-yl thio} acetic acid (3g). IR
(KBr, cm1): 3210.2 (OH), 3060.4 (Ar C–H), 2920.7 (OCH2),
2360.3 (CH2), 1710.6 (C‚O), 1600.3 (C‚N), 1545.8 (NO2),
768.7 (C–Cl).
1H NMR (400 MHz, DMSO-d6, d ppm): 12.1 (br, 1H, OH),
10.2 (s, 1H, HC‚N), 8.2–6.5 (m, 7H, Ar-H), 5.2 (s, 2H,
OCH2), 2.1 (s, 2H, CH2).
13C NMR (400 MHz, DMSO-d6, d ppm): 173.6 (C‚O),
162.8 (triazole-C3), 146.5 (triazole-C5), Ar C [152.3 (C1),
131.8 (C2), 130.6 (C3), 128.3 (C4 and C5), 117.4 (C6)], 157.8
(HC‚N), Ar C (benzylidene) [149.8 (C4), 139.6 (C1),
129.4 (C2 and C6), 127.6 (C3 and C5)], 62.3 (OCH2), 33.7
(S–CH2).
MS (ESI): m/z 482.2; calcd. 482.4.
2.2.3.8. 2-{5-[(2,4-Dichlorophenoxy)methyl]-4-(4-methoxyb-
enzylideneamino)-4H-1,2,4-triazol-3-yl thio} acetic acid (3h).
IR (KBr, cm1): 3200.2 (OH), 3060.2 (Ar C–H), 2915.6
(OCH2), 2350.2 (CH2), 1725.6 (C‚O), 1610.3 (C‚N), 872.4
(C–Cl).1H NMR (400 MHz, DMSO-d6, d ppm): 11.2 (s, 1H, OH),
10.1 (s, 1H, HC‚N), 7.5–6.6 (m, 7H, Ar-H), 5.2 (s, 2H,
OCH2), 3.7 (s, 3H, OCH3), 2.5 (s, 2H, CH2).
MS (ESI): m/z 467.2 calcd. 467.3
2.2.3.9. 2-{5-[(2,4-Dichlorophenoxy)methyl]-4-(2-hydroxyben-
zylideneamino)-4H-1,2,4-triazol-3-yl thio} acetic acid (3i). IR
(KBr, cm1): 3208.6 (OH), 3057.0 (Ar C–H), 2903.4
(OCH2), 2350.7 (CH2), 1720.3 (C‚O), 1610.3 (C‚N), 872.4
(C–Cl).
1H NMR (400 MHz, DMSO-d6, d ppm): 11.9 (s, 2H, OH),
10.4 (s, 1H, N‚CH), 7.2–6.6 (m, 7H, Ar-H), 5.2 (s, 2H,
OCH2), 2.8 (s, 2H, CH2).
13C NMR (400 MHz, DMSO-d6, d ppm): 173.8 (C‚O),
162.7 (triazole-C3), 147.3 (triazole-C5), Ar C [152.7 (C1),
131.3 (C2), 130.5 (C3), 128.1 (C4 and C5), 116.9 (C6)], 156.9
(HC‚N), Ar C (benzylidene) [159.8 (C2), 132.8 (C4), 130.2
(C6), 118.6 (C1), 117.3 (C3 and C5)], 62.9 (OCH2), 34.6 (S–
CH2).
MS (ESI) (M1): m/z 452.3; calcd. 453.3.
2.2.3.10. 2-{4-(2,4-Dichlorobenzylideneamino)-5-[(2,4-dichlo-
rophenoxy)methyl]-4H-1,2,4-triazol-3-yl thio} acetic acid (3j).
IR (KBr, cm1): 3110.4 (OH), 3065.6 (Ar C–H), 2930.3
(OCH2), 2363.6 (CH2), 1720.3 (C‚O), 1610.5 (C‚N), 795.3
(C–Cl).
1H NMR (400 MHz, DMSO-d6, d ppm): 13.1 (s, 1H, OH),
10.3 (s, 1H, N‚CH), 7.2–6.5 (m, 6H, Ar-H), 5.2 (s, 2H,
OCH2), 2.7 (s, 2H, CH2).
13C NMR (400 MHz, DMSO-d6, d ppm): 173.0 (C‚O),
162.5 (triazole-C3), 146.6 (triazole-C5), Ar C [151.9 (C1),
131.4 (C2), 131.7 (C3), 127.9 (C4 and C5), 117.9 (C6)], 158.2
(HC‚N), Ar C (benzylidene) [139.3 (C4), 136.42(C2), 132.2
(C6), 131.3 (C1), 129.4 (C3 and C5)], 60.4 (OCH2), 34.3
(S–CH2).
MS (ESI): m/z 506.4; calcd. 506.3.
2.2.3.11. 2-{5-[(2,4-Dichlorophenoxy)methyl]-4-(4-chloroben-
zylideneamino)-4H-1,2,4-triazol-3-yl thio} acetic acid (3k). IR
(KBr, cm1): 3210.2 (OH), 3060.4 (Ar C–H), 2920.7
(OCH2), 2360.3 (CH2), 1712.3 (C‚O), 1600.3 (C‚N), 856
(C–Cl).
1H NMR (400 MHz, DMSO-d6, d ppm): 13.2 (br, 1H, OH),
10.2 (s, 1H, HC‚N), 7.6–6.5 (m, 7H, Ar-H), 5.2 (s, 2H,
OCH2), 2.8 (s, 2H, CH2).
MS (ESI) (M+1): m/z 472.8; calcd. 471.7.
2.2.3.12. 2-{5-[(2,4-Dichlorophenoxy)methyl]-4-(4-methylben-
zylideneamino)-4H-1,2,4-triazol-3-yl thio} acetic acid (3l). IR
(KBr, cm1): 3200.8 (OH), 3063.0 (Ar C–H), 2914.4 (OCH2),
2351.3 (CH2), 1720.3 (C‚O), 1613.5 (C‚N), 872.4 (C–Cl).
1H NMR (400 MHz, DMSO-d6, d ppm): 11.7 (s, 1H, OH),
10.4 (s, 1H, N‚CH), 7.5–6.6 (m, 7H, Ar-H), 5.2 (s, 2H,
OCH2), 2.9 (s, 2H, CH2), 2.3 (s, 3H, CH3).
13C NMR (400 MHz, DMSO-d6, d ppm): 172.8 (C‚O),
162.7 (triazole-C3), 147.3 (triazole-C5), Ar C [152.2 (C1),
123.8 (C2), 131.0 (C3), 129.0 (C4 and C5), 117.2 (C6)], 157.5
(HC‚N), Ar C (benzylidene) [139.9 (C4), 130.2 (C2 and C6),
129.5 (C1), 117.3 (C3 and C5)], 62.3 (OCH2), 34.8 (S–CH2),
24.4 (CH3).
MS (ESI) (M+1): m/z 452.3; calcd. 451.3.
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3.1. Animals
Albino mice of either sex weighing between 20 and 25 g were
used for acute toxicity and analgesic activity studies. Healthy
male albino adult rats weighing between 150 and 230 g were
used for anti-inﬂammatory and ulcerogenic activities. Animal
ethical clearance was obtained from Ethics Committee of
K.S. Hegde Medical Academy, Deralakatte, Mangalore, India
(115/1999/CPCSEA). Animals were procured from K.S.
Hegde Medical Academy, Deralakatte, Mangalore, India,
and housed individually in polypropylene cages, maintained
under standard conditions of alternating 12-h light-and-dark
cycles at a constant temperature (25 ± 2 C and 35–60%
relative humidity). Animals were fed with standard rat pellet
diet, (Hindustan Lever Ltd., Mumbai, India) and water ad
libitum.
3.2. Acute toxicity
The acute toxicity test was carried out according to OECD
guidelines (OECD, 2000) to establish the effective dose of
the test compounds after obtaining ethical clearance from
Ethics Committee of K.S. Hegde Medical Academy, Deralak-
atte, Mangalore, India. Albino mice of either sex weighing
between 20 and 25 g were divided into six groups of 6 ani-
mals each. Animals were starved for 24 h with water ad libi-
tum prior to test. On the day of the experiment, animals were
administered with different compounds to different groups in
an increasing dose of 10, 20, 100, 200, 1000 and 2000 mg/kg
body weight orally. The animals were then observed continu-
ously for 3 h for general behavioral, neurological, autonomic
proﬁles and then every 30 min for next 3 h and ﬁnally for
next 24 h or till death.
From preliminary toxicity studies, it was observed that ani-
mals were found to be safe up to a maximum dose of 2000 mg/
kg body weight. But there were few changes in the behavioral
response like alertness, touch response, and restlessness. There-
fore, 1/10th of the maximum tolerated dose, i.e. 200 mg/kg
body weight (b.w.) was chosen for the studies.
3.3. In vivo anti-inﬂammatory activity
In vivo anti-inﬂammatory activity was evaluated by carra-
geenan-induced rat paw edema assay model (Winter et al.,
1962) for the compounds listed in Table 1. Male albino rats
(170–220 g) of either sex were used. The animals were divided
randomly into fourteen groups of six each. They were starved
overnight with water ad libitum prior to the day of experiment.
Control group received 1 ml of 0.5% sodium carboxymethyl
cellulose (sodium CMC), standard group received 13.5 mg/kg
diclofenac and test groups received 200 mg/kg of synthesized
compounds 3a–l orally. One hour later; a sub plantar injection
of 0.05 ml of 1% solution of carrageenan (Sigma) in sterile dis-
tilled water was administered to the left hind footpad of each
animal. The paw edema volume was measured with a digital
plethysmometer at 0, 1, 2, 3, 4, 5 and 6 h after carrageenan
injection. Paw edema volume was compared with vehicle con-
trol group and percent reduction was calculated as
% edema inhibition ¼ 1 Vt=Vc 100where, Vt and Vc were edema volume in treated and control
groups, respectively.
3.4. Analgesic activity (Koster et al., 1959)
Twenty-four hours prior to actual testing a large number of al-
bino mice of either sex weighing between 20 and 25 g received
intraperitoneally 10 mg/kg 0.6% glacial acetic acid. Animals
were observed for writhing movements. Only those showing
one or other type of writhing movements (positive responders)
were chosen for the test on the next day. On the test day the
responders received compounds half an hour prior to glacial
acetic acid challenge. Compounds 3d, 3e, 3j and 3k were orally
administered at a dose of 200 mg/kg as a suspension in 0.5%
sodium CMC. Standard drug used was aspirin at a dose of
30 mg/kg as a suspension in 0.5% sodium CMC. Each mouse
was then observed for the total number of stretching episodes
or writhings for 15 min following glacial acetic acid injection.
The mean value for each group was calculated.
3.5. Gastric ulceration (Alich et al., 1983)
Rats of either sex were fasted for 24 h. Test compounds and
positive control Aspirin were administered at a dose of
250 mg/kg p.o. in a group of six rats. Similarly the negative
controls were treated with 10 ml/kg 0.5% sodium CMC. Four
hours after treatment, the rats were sacriﬁced; the stomach was
removed, opened along the lesser curvature and observed for
gastric lesions on the mucosa. The lesion index for each group
was determined according to a previously reported method, by
counting the number of lesions (x) in each of ﬁve size classes
(y). The classes were deﬁned as y= 1 (pinpoint lesion), y=
2 (lesions < 1 mm diameter), y= 3 (lesions 1–2 mm diame-
ter), y= 4 (lesions 2–4 mm diameter) and y= 5 (lesions >
4 mm diameter). The lesions index was calculated using the
formula
P5
i¼1xiyi.
3.6. Statistical analysis
Data were presented as arithmetic mean ± SEM. Statistical
analysis was performed by one way variance (ANOVA)
followed by Dunnett’s test. ‘‘p’’ value of less than 0.05 was
considered as statistically signiﬁcant using PARAMETRIC
STASTICS, IBM PC version 1.01 by Londan soft ware
INC-1985.4. Results and discussion
A novel series of 2-[4-(substituted benzylideneamino)-
5-(substituted phenoxymethyl)-4H-1,2,4-triazol-3-yl thio]
acetic acid derivatives (3a–l) were synthesized as shown in
Scheme 1 by the reaction between thiocarbohydrazide and
substituted phenoxy acetic acid, which on fusion will yield 3-
(substituted phenoxymethyl)-4-amino-5-mercapto-1,2,4-tria-
zoles (1). Compound 1 was treated with various substituted
aromatic aldehydes in ethanol medium in presence concen-
trated hydrochloric acid at 90 C for 2 h. It resulted in 2a–g,
which converted to compounds 3a–l by the reaction with chlo-
roacetic acid in absolute ethanol medium in presence of drop
of pyridine as catalyst and reﬂuxed for 2–3 h. The purity of
the compounds was conﬁrmed by TLC using silica gel G as
Table 1 Characterization data of 4-(substituted benzylideneamino)-5-(substituted phenoxymethyl)-2H-1,2,4-triazole-3(4H)-thione
(2a-g) and 2-[4-(substituted benzylideneamino)-5-(substituted phenoxymethyl)-4H-1,2,4-triazol-3-yl thio] acetic acid derivatives (3a-l).
O
NN
N
N
SH
R
R1
2a-g
O
NN
N
N
S
R
R1
OH
O
3a-l
Compd. No. R R1 Yield (%) Melting Point* (0C) Rf Value
# Mol. Formula Analysis (%)
Found (Calculated)
C H N
2a H 4-CH3 67.0 202-204 0.36 C17H16N4OS 62.92 4.95 17.29
(62.94) (4.97) (17.27)
2b 2,4-Cl 4-NO2 68.2 186-188 0.42 C16H11Cl2N5O3S 45.33 2.65 16.53
(45.30) (2.61) (16.51)
2c 2,4-Cl 4-OCH3 65.0 189-191 0.36 C17H14Cl2N4O2S 49.88 3.44 13.67
(49.89) (3.45) (13.69)
2d 2,4-Cl 2-OH 65.0 202-204 0.28 C16H12Cl2N4O2S 48.63 3.07 14.16
(48.62) (3.06) (14.17)
2e 2,4-Cl 2,4-Cl 61.0 180-182 0.24 C16H10Cl4N4OS 42.85 2.23 12.52
(42.88) (2.25) (12.50)
2f 2,4-Cl 4-Cl 66.8 198-200 0.16 C16H11Cl3N4OS 46.44 2.65 13.53
(46.45) (2.68) (13.54)
2g 2,4-Cl 4-CH3 63.0 170-172 0.22 C17H14Cl2N4OS 51.91 3.57 14.21
(51.92) (3.59) (14.25)
3a H 4-NO2 63.0 148-150 0.29 C18H15N5O5S 52.31 3.65 16.92
(52.30) (3.66) (16.94)
3b H 4-OCH3 69.0 199-201 0.46 C19H18N4O4S 57.25 4.53 14.07
(57.27) (4.55) (14.06)
3c H 2- OH 71.1 210-212 0.36 C18H16N4O4S 56.26 4.23 14.56
(56.24) (4.20) (14.57)
3d H 2,4-Cl 70.0 158-160 0.42 C18H14Cl2N4O3S 49.46 3.21 12.83
(49.44) (3.23) (12.81)
3e H 4-Cl 72.2 186-188 0.43 C18H15ClN4O3S 53.69 3.74 13.94
(53.67) (3.75) (13.91)
3f H 4-CH3 68.4 175-177 0.33 C19H18N4O3S 59.68 4.73 14.64
(59.67) (4.74) (14.65)
3g 2,4-Cl 4-NO2 67.0 160-162 0.41 C18H13Cl2N5O5S 44.84 2.70 14.56
(44.83) (2.72) (14.52)
3h 2,4-Cl 4-OCH3 67.2 190-192 0.34 C19H16Cl2N4O4S 48.85 3.42 11.98
(48.83) (3.45) (11.99)
3i 2,4-Cl 2- OH 65.2 182-184 0.45 C18H14Cl2N4O4S 47.68 3.13 12.37
(47.69) (3.11) (12.36)
3j 2,4-Cl 2,4-Cl 68.4 178-180 0.36 C18H12Cl4N4O3S 42.72 2.42 11.05
(42.71) (2.39) (11.07)
3k 2,4-Cl 4-Cl 68.5 204-206 0.42 C18H13Cl3NO3S 45.84 2.80 11.85
(45.83) (2.78) (11.88)
3l 2,4-Cl 4-CH3 70.3 174-176 0.36 C19H16Cl2N4O3S 50.59 3.56 12.44
(50.56) (3.57) (12.41)
* Recrystallization with ethanol. # Stationary Phase: Silica gel G, Mobile phase: Chloroform : Benzene (1:1), Iodine vapors as visualizing agent.
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and by melting point. Structure of all the newly synthesized
compounds is well supported by the spectral data such as
IR, 1H NMR, 13C NMR, mass and elemental analysis. The
physical data of compounds is tabulated in Table 1.
The IR spectrum of compound 1 showed characteristic
absorption bands at 3457.4 cm1 due to NH2 and the other
at 1282.1/2580 cm1 was attributed to C‚S/SH. The 1H
NMR characteristic signal showed at d 13.2/7.8 as a singletdue to SH/NH proton derived from tautomeric equilibrium
of compound 1 and d 2.1 due to NH2 protons.
The IR spectrum of compound 2a–g showed a characteristic
absorption bands at range of 1588.5–1610.4 cm1 and 1531.3–
1535.7 cm1 due to the presence of HC‚N of Schiff base and
C‚N of triazole ring, respectively. The 1H NMR spectrum of
these compounds displayed a singlet at d 8.1 to d 10.4 which ac-
counted HC‚N. The 13C NMR data which displayed charac-
teristic signal at d 142.3 to d 155.9 due to HC‚N. It suggests
N
H
N
H
NH2H2N
S
+ O
OH
O
O
NN
N SH
R
R
O
NN
N
N
SH
R
1
3a-l
a
b
c
R1
O
NN
N
N
S
R
R1
2a-l
OH
O
NH2
O
NHN
N S
R
NH2
where R=H, 2,4-Cl
where R=H(1a), 2,4-Cl(1b)
Scheme 1 Synthesis of 2-[4-(substituted bezylideneamino)-5-(substituted phenoxymethyl)-4H-1,2,4-triazol-3-yl thio] acetic acid
derivatives (3a–l). Reagents and conditions: (a) Heat 175–180 C, oil bath, 2–3 h. (b) Aromatic aldehydes, absolute ethanol, reﬂux, 2 h.
(c) Chloroacetic acid, ethanol, reﬂux, 2–3 h.
Table 2 Anti-inﬂammatory activity of 2-[4-(substituted bezy-
lideneamino)-5-(substituted phenoxymethyl)-4H-1,2,4-triazol-
3-yl thio] acetic acid derivatives (3a–l).
Compound Paw mean
volume (±SEM)
Edema inhibition
at 3 h (%)
Control 0.443 ± 0.008 –
3a 0.339 ± 0.021 23.5
3b 0.330 ± 0.028 25.5
3c 0.328 ± 0.022 25.9
3d 0.162 ± 0.011** 63.4**
3e 0.168 ± 0.014** 62.0**
3f 0.345 ± 0.023 22.1
3g 0.322 ± 0.020* 27.3*
3h 0.322 ± 0.021* 27.3*
3i 0.316 ± 0.018* 28.6*
3j 0.159 ± 0.013** 64.1**
3k 0.166 ± 0.018** 62.5**
3l 0.320 ± 0.006* 27.8*
Diclofenac 0.146 ± 0.017** 67.0**
Dose of 200 mg/kg b.w., p.o.
* p 6 0.05.
** p 6 0.001.
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further conformed by evidence for the formation of Schiff base,
which was obtained by mass spectral data.
The IR spectrum of compound 3a–l showed characteristic
absorption bands at range of 3098.8–3210.2 cm1 was attrib-
uted to OH and 1710.6–1735.1 cm1 accounting for C‚O of
carboxyl group. The 1H NMR spectrum of these compounds
displayed a broad singlet at d 13.5 to d 13.9 due to OH of car-
boxyl group and singlet at d 1.1 to d 2.9 due to S–CH2 protons
indicates the formation of S–CH2–COOH at 5th position of
triazole. The 13C NMR data observed characteristic singlet
at d 29.5 to d 39.4 due to S–CH2. It reveals the formation of
thioacetic acid by the reaction of SH with chloroacetic acid.
The structure of compounds was further supported by mass
spectral data.
All compounds 3a–l were subjected for preliminary toxicity
studies, according to Organization for Economic Co-operation
and Development (OECD) guidelines in mice. Compounds
were found to be safe up to 2000 mg/kg body weight (b.w.).
Therefore 1/10th of the maximum tolerated dose, i.e.,
200 mg/kg b.w. was used as therapeutic dose.
Acute anti-inﬂammatory activity by carrageenan induced
rat paw edema model by Winter et al. Diclofenac was used
as reference standard. The anti-inﬂammatory activity results
revealed that the compounds 3d, 3e, 3j and 3k exhibited signif-
icant anti-inﬂammatory activity (up to 63.4%, 62.0%, 64.1%
and 62.5% edema inhibition, respectively), as compared to
the standard drug diclofenac (67.0%) after third hour. Where
as compounds 3g–i, 3l showed good anti-inﬂammatory activity
and among compounds 3a–c, 3f showed lesser degree anti-inﬂammatory activity compared to that of standard drug
Diclofenac. The anti-inﬂammatory activity of these com-
pounds may be attributed to the inhibition of cyclooxygenase
enzyme, which plays vital role in the inﬂammation process.
The results indicating the percentage inhibition of inﬂamma-
tion have been shown in Table 2.
Table 3 Analgesic activity of 2-[4-(substituted bezylideneami-
no)-5-(substituted phenoxymethyl)-4H-1,2,4-triazol-3-yl thio]
acetic acid derivatives (3a–l).
Compound No. of wriths in 15 min
(mean ± SEM)
(%) Protection
Control 68.6 ± 7.0 –
3d 31.3 ± 3.4 53.9*
3e 31.8 ± 7.6 53.6*
3j 30.2 ± 8.3 55.9**
3k 30.9 ± 3.6 54.9**
Aspirin 29.0 ± 5.6 57.8**
Dose of 200 mg/kg b.w., p.o.
* p 6 0.05.
** p 6 0.001.
Synthesis, anti-inﬂammatory and analgesic activity 1077Abdominal construction responses induced by acetic acid is
a sensitive procedure to establish efﬁcacy of peripherally-
acting analgesics, it may causes increase in the level of PGE2
and PGF2a by intraperitoneally administration of acetic acid.
The analgesic activity was expressed as percentage of protec-
tion. Among the series compounds 3j, 3k showed signiﬁcant
analgesic activity (up to 55.9%, 54.9%protection, respectively),
where as among compounds3d, 3e showed good analgesic activ-
ity (up to 53.9%, 53.6% protection, respectively), as compared
to the standard drug aspirin (57.8%) as illustrated in Table 3.
Among the compounds 3d, 3e, 3j and 3k, the compound 3j
showed highest anti-inﬂammatory and analgesic activities
because of two chlorine groups at ortho and para position
on both phenoxymethyl ring and imine phenyl ring. Hence,
it reveals that the compounds having more than one electron
withdrawing group (halogen) on phenoxymethyl ring and
imine phenyl ring showed increasing anti-inﬂammatory and
analgesic activities.
The major drawback of non steroidal anti-inﬂammatory
drugs is their gastric side effects. In order to determine the
extent of these effects, the compounds 3d, 3e, 3j and 3k were
further tested for ulcerogenicity (Rainsford, 1975) in rats at
200 mg/kg. All four compounds showed comparable ulcero-
genic activity when compared to standard drug aspirin.
Among these 3j, 3k showed less ulcerogenic activity, respec-
tively. Results are shown in Table 4.
5. Conclusion
The present study revealed that the synthesis of the title com-
pounds had satisfactory yields. It was observed that the testTable 4 Ulcerogenic activity of 2-[4-(substituted bezylidenea-
mino)-5-(substituted phenoxymethyl)-4H-1,2,4-triazol-3-yl
thio] acetic acid derivatives (3a–l).
Compound Ulcer index ± SEM
Control 1.4 ± 0.45
3d 4.7 ± 1.33*
3e 4.5 ± 1.26*
3j 3.9 ± 1.22*
3k 3.6 ± 1.30*
Aspirin 5.3 ± 1.55*
Dose 200 mg/kg p.o.
* p 6 0.05.compounds 3j and 3k containing electron withdrawing moiety
(halogen) on phenyl group of Schiff base as well as on phen-
oxymethyl were found to have signiﬁcant anti-inﬂammatory
and analgesic activity compared to the standard. Results of
these compounds showed less ulcerogenic activity to aspirin.
These can be regarded as strong candidates for future
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